Loading
A phase 1/2 trial of an investigational treatment in non-Hodgkin lymphoma, run by Otsuka Medical Devices Co., Ltd. Japan, now recruiting.
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma is a phase 1/2 interventional study registered as NCT07075328 by Otsuka Medical Devices Co., Ltd. Japan, with 49 participants planned, started 2024-04-01 and due to reach its primary completion in 2028-02-28.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Otsuka Pharmaceutical and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Otsuka Pharmaceutical and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/